Exemestane vs. Letrozole: A Detailed Comparison

Exemestane and letrozole both belong to the aromatase inhibitor (AI) class used primarily in hormone receptor-positive breast cancer, but they are not interchangeable twins. Exemestane is a steroidal AI that permanently disables the aromatase enzyme, while letrozole is a nonsteroidal AI that reversibly blocks it. This structural difference ripples outward into how deeply each drug suppresses estrogen, how it affects bones and cholesterol, and whether switching from one to the other can still work when the first one fails. A large 2025 study even found measurable differences in long-term survival outcomes between the two.

How They Work Differently at the Molecular Level

Both drugs accomplish the same basic task: they shut down aromatase, the enzyme that converts androgens into estrogen in postmenopausal women. But they do it through fundamentally different mechanisms. Letrozole binds reversibly to the active site of aromatase, competing with the enzyme’s natural substrate. When the drug is cleared from the body, the enzyme can resume its normal function. Exemestane, on the other hand, mimics the enzyme’s natural substrate and binds to it irreversibly, destroying the enzyme molecule permanently. New aromatase activity can only return once the body manufactures fresh enzyme.

This irreversible-versus-reversible distinction matters clinically because it means the two drugs can sometimes work in sequence. A tumor that has stopped responding to letrozole may still respond to exemestane, and vice versa. It also gives exemestane a mild androgenic character, because its steroidal structure allows some of its metabolites to interact with androgen receptors, something letrozole cannot do.

Estrogen Suppression Is Not Equal

If you assume that all aromatase inhibitors suppress estrogen to roughly the same degree, the research says otherwise. In a neoadjuvant study that directly compared the two drugs using a crossover design, letrozole suppressed serum estrone to a mean of 0.2 pmol/L and estradiol to 0.4 pmol/L. Exemestane brought estrone down to 1.8 pmol/L and estradiol to 0.6 pmol/L. When patients who had been on exemestane crossed over to letrozole, their estrogen levels dropped further. When patients who had been on letrozole crossed over to exemestane, their estrogen levels actually rose.¹ That is a meaningful gap, because suboptimal estrogen suppression has been linked to higher recurrence risk.²

The difference in estrogen suppression is not subtle. Letrozole achieved estrone levels roughly nine times lower than exemestane in the same patients. Whether that translates into proportionally better cancer control is a separate question, because cancer outcomes depend on many factors beyond raw estrogen levels. But the pharmacological gap is real and consistently demonstrated.

Long-Term Survival and Disease-Free Outcomes

A 2025 observational study published in JAMA Network Open followed a large cohort of postmenopausal breast cancer patients treated with one of the three available aromatase inhibitors: exemestane, letrozole, or anastrozole. After a median follow-up of about five years, the eight-year disease-free survival was estimated at 79.1% for exemestane, compared with 81.1% for letrozole and 81.0% for anastrozole. Eight-year overall survival followed a similar pattern: 88.8% for exemestane versus 89.9% for letrozole and 90.5% for anastrozole.³

Those gaps are not dramatic in absolute terms, roughly two percentage points for disease-free survival and about one percentage point for overall survival. But for a disease where thousands of patients are treated, even small absolute differences apply to a large number of people. The study also found that this difference persisted even after statistically accounting for treatment discontinuation, meaning it was not simply a matter of patients on exemestane stopping their pills sooner. The authors noted that the stronger estrogen suppression achieved by letrozole could plausibly explain the difference.⁴

It is worth noting that this was an observational study, not a randomized trial directly pitting exemestane against letrozole. No such head-to-head randomized trial for adjuvant therapy exists between these two drugs, which is a significant gap in the evidence. Real-world observational data like this can be influenced by differences in patient selection that statistical methods only partially correct for. Still, the findings align with what the estrogen suppression data would predict.

Why Switching Between Them Can Still Work

Because exemestane and letrozole disable aromatase through different mechanisms, a tumor that progresses on one drug may still respond to the other. This is called non-cross-resistance, and it is one of the most practical advantages of having two structurally different AIs available. In a study of 23 patients whose cancer had progressed on letrozole or anastrozole (both nonsteroidal AIs), switching to exemestane produced clinical benefit in about 44% of cases, with a median time to further progression of just over five months.⁵ Five months may not sound like much, but in advanced breast cancer that has already failed one line of hormonal therapy, it represents meaningful disease control.

Case reports further illustrate this principle. One documented case described a patient with recurrent metastatic breast cancer who achieved a sustained complete remission after switching from a nonsteroidal AI to exemestane, resulting in years of disease control and improved quality of life.⁶ Single cases do not prove a general principle, but this one illustrates the clinical rationale: the two drug classes are different enough at the molecular level that resistance to one does not automatically mean resistance to the other.

The reverse sequence, switching from exemestane to letrozole, is used less commonly in clinical practice, partly because letrozole tends to be prescribed first due to its stronger estrogen suppression. But the biological logic suggests it should work in some cases, and oncologists do use it.

Effects on Bone Health

Both exemestane and letrozole lower estrogen, and estrogen is a key protector of bone density in postmenopausal women. By pushing already-low estrogen levels to near-undetectable concentrations, aromatase inhibitors accelerate bone loss and increase fracture risk. This is a class-wide problem, not one confined to a single drug.⁷

Where the two drugs diverge is in the nuance. Exemestane’s mild androgenic activity may partially buffer the blow to bones, because androgens have their own modest bone-protective effects. Some preclinical and clinical data suggest that exemestane causes slightly less bone density loss than the nonsteroidal AIs, though this does not mean it is bone-safe. Any patient on either drug for years should be monitored with bone density scans and, depending on their baseline risk, may need bone-protective medications like bisphosphonates or denosumab.

In practice, the choice between exemestane and letrozole is rarely made on bone health alone. But for a patient who already has significant osteoporosis, this is one factor that might tip the balance, particularly if the oncologist judges the cancer risk to be similar enough on either drug.

Cholesterol and Cardiovascular Implications

The lipid profile effects of exemestane and letrozole move in notably different directions. A study comparing cholesterol changes in postmenopausal breast cancer patients found that exemestane significantly reduced HDL (the “good” cholesterol) while leaving LDL relatively unchanged. Letrozole, by contrast, left HDL alone but significantly raised LDL. The investigators noted that some of the LDL increase with letrozole was at least partly attributable to the washout effect of prior tamoxifen therapy rather than a pure letrozole effect.⁸

Animal data adds another layer. In ovariectomized rats, exemestane and its primary metabolite actually reduced total cholesterol and LDL cholesterol, while letrozole-treated animals showed lipid levels similar to untreated controls.⁹ Rat data does not translate directly to humans, but it suggests that exemestane’s steroidal backbone might interact with lipid metabolism in ways that letrozole’s structure does not.

Neither drug has a clean cardiovascular profile. Both are used in patients already at elevated cardiovascular risk due to age, and both alter lipids in unfavorable ways, just different unfavorable ways. A patient with very low HDL at baseline might be more concerned about exemestane; a patient with already-elevated LDL might worry more about letrozole. In either case, ongoing lipid monitoring and cardiovascular risk management are part of responsible treatment.

Exemestane’s Androgenic Edge

Exemestane is unique among the three available aromatase inhibitors in possessing mild androgenic activity, a consequence of its steroidal structure.¹⁰ This has real clinical implications beyond the bone and lipid effects already discussed. Some of the most burdensome side effects of aromatase inhibitors, particularly hot flashes and joint pain, are driven by the steep drop in estrogen. Androgenic activity may partially counterbalance the symptomatic consequences of estrogen depletion.

This is one reason clinicians sometimes switch a patient from letrozole to exemestane when side effects are severe. The goal is not necessarily better cancer control but rather tolerable cancer control. If a patient’s quality of life on letrozole has deteriorated to the point where she is considering stopping treatment altogether, switching to exemestane can sometimes preserve adherence by making the side-effect burden more manageable. The androgenic effect is not strong enough to cause masculinizing symptoms at standard doses, but it may be just enough to soften the worst menopausal symptoms.

Adherence and Discontinuation

No cancer drug works if a patient stops taking it, and aromatase inhibitors have a well-documented adherence problem. These drugs are prescribed for five to ten years, and the side effects, especially joint stiffness, fatigue, and menopausal symptoms, accumulate over time. The 2025 JAMA study found that patients who started on exemestane were more likely to discontinue treatment within five years than those on letrozole: about 39% versus 35%.³

A randomized adherence trial found a similar pattern, with exemestane showing a shorter time to treatment discontinuation compared to letrozole.¹¹ This is somewhat counterintuitive given exemestane’s androgenic properties, which in theory should make it more tolerable. One possible explanation is that letrozole’s once-daily pill is better tolerated in practice for reasons unrelated to pharmacology, such as formulation or the specific pattern of side effects. Another is that prescribing patterns differ: patients started on exemestane may differ systematically from those started on letrozole in ways that affect adherence.

Regardless of the reason, the adherence gap matters because it feeds directly into the survival difference. If you stop your AI early, you lose the cancer-protective benefit of the remaining years. The JAMA study tried to control for this by estimating outcomes under hypothetical perfect adherence, and the exemestane disadvantage persisted, suggesting that adherence is not the whole story. But it is part of the story.

Organ Impairment and Drug Clearance

How your liver and kidneys function affects how your body handles these drugs, and the two AIs differ here. Exemestane exposure increases two- to threefold in patients with moderate to severe liver impairment, meaning the drug circulates at much higher concentrations than intended. A similar two- to threefold increase occurs with moderate to severe kidney impairment.¹² Despite the higher drug levels, the study found no acute safety concerns, and exemestane’s prescribing information does not mandate dose adjustments. But for patients with significant organ dysfunction, the substantially elevated drug levels are worth knowing about, particularly during long-term treatment.

Letrozole is also metabolized by the liver, primarily through the CYP3A4 and CYP2A6 enzyme pathways, but its pharmacokinetics in hepatic impairment have been characterized separately. In general, both drugs require attention to liver function, but exemestane’s documented two- to threefold increase in exposure makes it the drug more likely to accumulate in a patient with compromised organ function.

Genetic Variation and Individual Response

Not every patient responds identically to the same aromatase inhibitor, and researchers are beginning to understand why. A study on exemestane identified a set of genetic variants in enzymes involved in drug metabolism, drug transport, and DNA repair that, when combined into a risk score, powerfully predicted how long a patient would benefit from the drug. Patients with the lowest genetic risk score had a median progression-free survival of over 26 months on exemestane, while those with the highest risk score had a median of just 10 months. Overall survival showed a similar gap: 63 months versus about 39 months.¹³

This kind of pharmacogenomic profiling is not yet routine in clinical practice, but it points toward a future where the choice between exemestane and letrozole could be guided by a patient’s genetic makeup rather than population-level averages. If your genetic profile predicts poor exemestane metabolism or rapid resistance, starting with letrozole might make more sense, and vice versa. For now, these tools remain research-grade rather than clinic-ready, but the direction of the science is clear.

Aromatase Inhibitors in Fertility Treatment

Both exemestane and letrozole have a life beyond oncology. Letrozole has become widely used in reproductive medicine as an ovulation induction agent, particularly for women with polycystic ovary syndrome. By temporarily lowering estrogen, letrozole tricks the brain into releasing more follicle-stimulating hormone, prompting the ovaries to develop and release eggs. Research has found aromatase inhibitors to be useful for ovulation induction in PCOS and as a treatment option for superovulation in patients with unexplained infertility or endometriosis.¹⁴

Letrozole dominates this space for practical reasons. Its reversible mechanism means that once the drug is cleared, estrogen production bounces back quickly, which is exactly what you want during a fertility cycle. Exemestane’s irreversible binding would in theory cause a slower and less predictable recovery of estrogen, making cycle timing harder to control. Exemestane is therefore rarely used in fertility settings, even though both drugs block the same enzyme. The pharmacological difference that is a footnote in oncology becomes the deciding factor in reproductive medicine.

Practical Considerations for Patients

Exemestane is taken with food, which increases its absorption substantially. Missing the meal and taking it on an empty stomach meaningfully reduces drug levels. Letrozole can be taken with or without food, giving it a slight convenience advantage for patients who do not eat on a regular schedule. Both drugs are taken once daily, and both are available as generics, making cost differences between them generally small in most health systems.

If you are currently on one of these drugs and wondering whether you should switch to the other, the honest answer is that the decision is deeply individual. Letrozole produces stronger estrogen suppression and modestly better long-term outcomes in the available data. Exemestane offers a different side-effect profile, a potential escape route when letrozole stops working, and mild androgenic properties that may help with tolerability. For most patients, the oncologist’s choice between the two is shaped by tumor characteristics, the patient’s comorbidities (bone health, cardiovascular risk, liver function), prior treatment history, and, frankly, which drug the patient can tolerate well enough to keep taking for years. Neither drug is categorically superior; each has trade-offs the other does not.